Autoimmunity in Anti-Glomerular Basement Membrane Disease: A Review of Mechanisms and Prospects for Immunotherapy.
anti-GBM disease
autoimmunity
epitope mapping
epitope mimicry
epitope spreading
glomerular basement membrane (GBM)
glomerulonephritis (GN)
immunotherapy
kidney injury
review
α3(IV)NC1
Journal
American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
28
04
2022
accepted:
10
07
2022
pubmed:
6
11
2022
medline:
24
12
2022
entrez:
5
11
2022
Statut:
ppublish
Résumé
Anti-glomerular basement membrane (anti-GBM) disease is an organ-specific autoimmune disorder characterized by autoantibodies against the glomerular and alveolar basement membranes, leading to rapidly progressive glomerulonephritis and severe alveolar hemorrhage. The noncollagenous domain of the α3 chain of type IV collagen, α3(IV)NC1, contains the main target autoantigen in this disease. Epitope mapping studies of α3(IV)NC1 have identified several nephritogenic epitopes and critical residues that bind to autoantibodies and trigger anti-GBM disease. The discovery of novel target antigens has revealed the heterogeneous nature of this disease. In addition, both epitope spreading and mimicry have been implicated in the pathogenesis of anti-GBM disease. Epitope spreading refers to the development of autoimmunity to new autoepitopes, thus worsening disease progression, whereas epitope mimicry, which occurs via sharing of critical residues with microbial peptides, can initiate autoimmunity. An understanding of these autoimmune responses may open opportunities to explore potential new therapeutic approaches for this disease. We review how current advances in epitope mapping, identification of novel autoantigens, and the phenomena of epitope spreading and mimicry have heightened the understanding of autoimmunity in the pathogenesis of anti-GBM disease, and we discuss prospects for immunotherapy.
Identifiants
pubmed: 36334986
pii: S0272-6386(22)00855-1
doi: 10.1053/j.ajkd.2022.07.006
pii:
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
Collagen Type IV
0
Epitopes
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
90-99Informations de copyright
Copyright © 2022 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.